ACCEL Lite: Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy

This study evaluates the potential impact of Mavacamten in severely symptomatic patients with obstructive hypertrophic cardiomyopathy to reduce the need for septal reduction therapy. It studies a first of its kind new cardiac myosin inhibitor. In this interview, Milind Desai MD, MBA and Matthew Martinez MD, FACC, with Zain Ul Abideen Asad MD, discuss this ACC.22 Late Breaker: Mavacamten as an Alternative To Surgical Septal Myectomy Or Alcohol Ablation In Patients With Severely Symptomatic Obstructive Hypertrophic Cardiomyopathy.